MIM
ABBV icon

Moseley Investment Management’s AbbVie ABBV Stock Holding History

Moseley Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Sell
7,796
-191
-2% -$42.4K 0.54% 45
2025
Q4 		$1.82M Sell
7,987
-43
-0.5% -$9.79K 0.56% 43
2025
Q3 		$1.86M Sell
8,030
-104
-1% -$21.2K 0.57% 47
2025
Q2 		$1.51M Buy
8,134
+21
+0.3% +$3.9K 0.52% 48
2025
Q1 		$1.7M Buy
8,113
+230
+3% +$44.7K 0.66% 40
2024
Q4 		$1.4M Buy
7,883
+120
+2% +$22.1K 0.55% 45
2024
Q3 		$1.53M Buy
7,763
+122
+2% +$22.8K 0.61% 41
2024
Q2 		$1.31M Buy
7,641
+68
+0.9% +$11.3K 0.61% 42
2024
Q1 		$1.38M Buy
7,573
+71
+0.9% +$12.2K 0.68% 39
2023
Q4 		$1.16M Sell
7,502
-4,547
-38% -$663K 0.65% 39
2023
Q3 		$1.8M Sell
12,049
-147
-1% -$21.6K 1.07% 22
2023
Q2 		$1.64M Buy
12,196
+843
+7% +$124K 0.96% 25
2023
Q1 		$1.81M Buy
11,353
+310
+3% +$47.4K 1.17% 22
2022
Q4 		$1.78M Sell
11,043
-46
-0.4% -$7.05K 1.28% 24
2022
Q3 		$1.49M Buy
11,089
+934
+9% +$134K 1.09% 23
2022
Q2 		$1.55M Buy
10,155
+328
+3% +$50.1K 1.09% 25
2022
Q1 		$1.59M Sell
9,827
-280
-3% -$40.7K 0.86% 34
2021
Q4 		$1.37M Buy
10,107
+106
+1% +$12.5K 0.62% 51
2021
Q3 		$1.09M Buy
10,001
+614
+7% +$70.2K 0.55% 60
2021
Q2 		$1.06M Buy
9,387
+570
+6% +$64.2K 0.52% 60
2021
Q1 		$954K Sell
8,817
-15
-0.2% -$1.6K 0.53% 56
2020
Q4 		$946K Buy
8,832
+965
+12% +$92.7K 0.55% 56
2020
Q3 		$689K Sell
7,867
-369
-4% -$34.7K 0.49% 58
2020
Q2 		$809K Buy
8,236
+843
+11% +$74.2K 0.67% 41
2020
Q1 		$563K Sell
7,393
-75
-1% -$6.39K 0.66% 48
2019
Q4 		$661K Sell
7,468
-1,524
-17% -$127K 0.65% 52
2019
Q3 		$681K Sell
8,992
-1,780
-17% -$122K 0.71% 47
2019
Q2 		$783K Buy
10,772
+3,122
+41% +$245K 0.73% 44
2019
Q1 		$617K Buy
+7,650
New +$626K 0.64% 48

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Moseley Investment Management's ABBV Position: Q1 2026 in Review

Moseley Investment Management reduced its AbbVie (ABBV) stake by 2.4% in Q1 2026, selling an estimated $42.4K and leaving 7,796 shares worth $1.7M. The position accounts for 0.54% of the portfolio, ranked #45.

Moseley Investment Management first reported a position in ABBV in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.86M in Q3 2025. 4,103 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Moseley Investment Management held 7,796 shares of AbbVie worth $1.7M as of Q1 2026.
  • Moseley Investment Management sold 191 AbbVie shares in Q1 2026, an estimated $42.4K.
  • AbbVie made up 0.54% of Moseley Investment Management's portfolio in Q1 2026, its #45 holding.
  • Moseley Investment Management first reported a position in AbbVie in Q1 2019 and has held it in 29 quarters since.
  • Moseley Investment Management's AbbVie position peaked at $1.86M in Q3 2025.
  • 4,103 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Moseley Investment Management's 13F filing for Q1 2026, filed 21 Apr 2026.